Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biologic Samples.
- Who it may be relevant to
- Registry conditions: Cutaneous Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.
Interventions
- Other Biologic Samples
* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care. * an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care. * In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.
Primary outcome measures
- overall survival [Time frame: 5 years]
Secondary outcome measures (3)
- Progression free survival [Time frame: 5 years]
- Progression free survival [Time frame: 10 years]
- Overall survival [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Age> 18 years old
- Informed consent signed by the patient
- Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to WHO/ISCL/EORTC criteria
Exclusion criteria
- Patient under guardianship or curatorship
- Lack of affiliation to social security
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT04520529 · APHP190179